Keyphrases
Antiangiogenic
100%
Peptide Hydrogel
100%
Neovascular
100%
Posterior Segment Diseases
100%
Diabetic Retinopathy
85%
Self-assembling Peptide Hydrogel
42%
Inflammation
42%
Neovascularization
42%
Retina
28%
Triamcinolone Acetonide
28%
Chronic Inflammatory Diseases
28%
Attenuation
14%
Site-directed Therapy
14%
Quality of Life
14%
Adult Population
14%
Low Risk
14%
Standard of Care
14%
Aberrant Vessel
14%
Drug Release Kinetics
14%
Delivery System
14%
Biocompatibility
14%
Patient Comfort
14%
Sustained Release
14%
Geriatric Population
14%
Microenvironment
14%
Immune Response
14%
Minority Populations
14%
Injectable Hydrogel
14%
Anti-VEGF Antibody
14%
Antiangiogenic Activity
14%
Working Adults
14%
In Vitro Anti-inflammatory Activity
14%
Long-term Efficacy
14%
Long-term Delivery
14%
Bevacizumab
14%
Synthetic Schemes
14%
Vascularization
14%
Kringle Domain
14%
Vascular Growth
14%
Laminin-1
14%
Small Molecules
14%
Histidine-proline-rich Glycoprotein
14%
Causes of Blindness
14%
Vessel Formation
14%
Injection Schedules
14%
Rodents
14%
Biofunctionality
14%
Release System
14%
Anti-inflammatory Steroids
14%
Intraocular Delivery
14%
Infection Risk
14%
Edema
14%
Endophthalmitis
14%
Anti-inflammatory Drugs
14%
Posterior Segment
14%
Patient Compliance
14%
Kringle 5
14%
In Situ
14%
Vascular Leakage
14%
Medicine and Dentistry
Disease
100%
Antiangiogenic
100%
Diabetic Retinopathy
85%
Kringle Domain
28%
Triamcinolone Acetonide
28%
Inflammatory Disorder
28%
In Vitro
28%
Proline
14%
Laminin 1
14%
Sustained Drug Release
14%
Deterioration
14%
Antiinflammatory Activity
14%
Vascularity
14%
Vasculotropin Antibody
14%
Bevacizumab
14%
Edema
14%
Quality of Life
14%
Patient Compliance
14%
Obstetric Delivery
14%
Histidine
14%
Antiangiogenic Activity
14%
Antiinflammatory Agent
14%
Anti-Inflammatory Drug
14%
Infection
14%
Glycoprotein
14%
Endophthalmitis
14%
Geriatrics
14%
Biocompatibility
14%
Immune Response
14%
Amaurosis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Antiangiogenic
100%
Diabetic Retinopathy
75%
Inflammation
37%
Neovascularization (Pathology)
37%
Anti-Inflammatory Drug
25%
Inflammatory Disease
25%
Triamcinolone Acetonide
25%
Sustained Release
12%
Antiinflammatory Agent
12%
Endophthalmitis
12%
Histidine
12%
Laminin 1
12%
Proline
12%
Glycoprotein
12%
Drug Release
12%
Bevacizumab
12%
Deterioration
12%
Biocompatibility
12%
Vasculotropin Antibody
12%
Edema
12%
Infection
12%